Alembic Pharma gets USFDA nod to market generic cancer drug
Docetaxel Injections are indicated for breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma and squamous cell carcinoma of head and neck. According to IQVIA data, Docetaxel injection has an estimated market size of USD 11 million in the US market.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Adenocarcinoma | Biotechnology | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Docetaxel | Gastric (Stomach) Cancer | Gastroenterology | Head and Neck Cancer | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals | Prostate Cancer | Skin Cancer | Squamous Cell Carcinoma | Taxotere